Global Drug Eluting Stents Market Projected to reach 12.5 Billion by 2033, Expanding at a CAGR of 6.1% | M2Square Consultancy
Global Drug Eluting Stents Market Projected to reach 12.5 Billion by 2033, Expanding at a CAGR of 6.1% | M2Square Consultancy
Published on November 13, 2025 | Category: Healthcare
Global Drug Eluting Stents Market
Projected to reach 12.5 Billion by 2033, Expanding at a CAGR of 6.1% | M2Square
Consultancy
The Global Drug-Eluting Stents Market is
entering a robust growth phase, propelled by increasing prevalence of coronary
and peripheral artery disease, continual innovations in stent design and
coatings, and expanding access to interventional cardiology services worldwide.
According to M2Square Consultancy's latest research report, the market is
projected to grow at a CAGR of 6.1% from 2025 to 2033, reaching an estimated
value of USD 12.5 billion by 2033.
Drug-eluting stents (DES) have transformed interventional
cardiology by reducing restenosis and improving long-term outcomes after
angioplasty. The rising global burden of cardiovascular diseases (CVDs),
responsible for nearly 18 million deaths annually according to the WHO (2024),
continues to drive the adoption of advanced coronary stents. Moreover, the
introduction of biodegradable polymer stents, next-generation drug
formulations, and AI-guided stent placement systems is revolutionizing cardiac
intervention practices across hospitals and specialty clinics.
The drug-eluting stent market is entering a new era where materials
science and drug delivery converge to improve patient outcomes, and that shift
creates significant commercial opportunities for companies that can demonstrate
both clinical benefit and system-level value. The shift toward biodegradable,
polymer-free, and nanotechnology-integrated stents will define the next phase
of market evolution. These innovations aim to enhance biocompatibility, healing
rates, and long-term patient outcomes.
The DES market is continuously evolving towards
less-is-more. The rapid adoption of third-generation stents, with their
ultrathin struts and advanced polymer coatings, directly correlates to better
long-term patient safety and reduced need for extended dual antiplatelet
therapy. The success of these devices solidifies the DES as the gold standard
for percutaneous coronary intervention (PCI) worldwide.
North America Drug-Eluting Stents Market Insights
North America is a dominant market led by high procedural
volumes and strong reimbursement. Key drivers for this growth include a high
prevalence of coronary artery disease (CAD) in the region, wide adoption of
advanced interventional cardiology procedures such as percutaneous coronary
interventions (PCI, favourable reimbursement systems, and ongoing technological
innovation in DES design, e.g., thinner-struts, biodegradable or polymer-free
coatings, enhanced deliverability. For instance, polymer-based coatings still
dominate, but polymer-free coatings are emerging as the fastest‐growing subsegment. The U.S. is expected to hold the major
share of the market. In the U.S., about ~600,000 PCIs per year are performed,
and over 965,000 angioplasties (PCIs) are performed each year in the United
States.
Key Market Highlights from the Report
●
Market
Valuation: The market was valued at an
estimated USD 7.8 billion in 2025.
●
Coating Type: Polymer-based coating. DES accounts for the largest share
due to proven drug delivery efficacy. Polymer-free and biodegradable polymer
stents are emerging strongly as next-generation technologies.
●
Application: Coronary artery disease (CAD) remains the dominant
segment due to the high volume of procedures; however, the peripheral artery
disease (PAD) segment is projected to grow at a faster rate.
●
Leading Region:
North America currently leads the
market, due to a mature interventional cardiology infrastructure and
reimbursement environment. Asia-Pacific is identified as one of the fastest-growing
regions.
Drug-Eluting Stents Market Segmentation
M2Square Consultancy has segmented the global Drug Eluting
Stents market based on coating type, drug type, application, end-user, and
region:
By Coating Type
●
Polymer-Based
Coatings
●
Non-biodegradable
Polymers
●
Biodegradable
Polymers
●
Polymer-Free
Coatings
●
Microporous
Surface
●
Microstructured
Surface
●
Slotted
Tubular Surface
●
Nanoporous
Surface
By Drug Type
●
Sirolimus
& Analogues
●
Paclitaxel
●
Others
By Application
●
Coronary
Artery Disease (CAD)
●
Peripheral
Artery Disease (PAD)
●
Others
By End-user
●
Hospitals
●
Ambulatory
Surgical Centers (ASCs)
●
Cardiac
Catheterization Laboratories (Cath Labs)
By Region
●
North
America
o U.S.
o Canada
●
Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Switzerland
o Rest of Europe
●
Asia
Pacific
o China
o India
o Japan
o South Korea
o Australia
o Rest of APAC
●
Latin
America
o Mexico
o Brazil
o Argentina
o Rest of LATAM
●
Middle
East & Africa
o Saudi Arabia
o UAE
o South Africa
o
Rest
of MEA
Key Market Players in the Drug-Eluting Stents Market
●
Abbott
Laboratories
●
Boston
Scientific Corporation
●
Medtronic
plc
●
Terumo
Corporation
●
Biotronik
SE & Co. KG
●
MicroPort
Scientific Corporation
●
Cook
Medical
●
B.
Braun Melsungen AG
●
Biosensors
International Group, Ltd.
●
Lepu
Medical Technology (Beijing) Co., Ltd.
●
Sahajanand
Medical Technologies Pvt. Ltd.
●
Alvimedica
Medical Technologies Inc.
●
OrbusNeich
Medical Group Holdings Ltd.
●
Shandong
JW Medical Systems Ltd.
●
Sino
Medical Sciences Technology Inc.
●
Others
Key Strategies by Drug-Eluting Stents Market Players
Biodegradable/Bioresorbable Polymers: The major shift is toward using
polymers that gradually dissolve after releasing the drug. This reduces the
risk of long-term complications like late stent thrombosis and promotes faster
healing of the arterial wall.
Polymer-Free Coatings: Developing stents where the drug is directly embedded into the
stent surface or micro-reservoirs. This strategy eliminates the polymer,
appealing to physicians who believe the polymer itself can cause inflammation
or delayed healing.
Implications for Stakeholders
●
Manufacturers & device
suppliers: Should focus on R&D for ultra-thin strut designs, bioabsorbable
or polymer-free coatings, enhanced deliverability, and cost-effective platforms
that meet emerging-market needs.
●
Healthcare providers &
interventional cardiology centres: Must evaluate stent choice not only on
upfront cost but also on long-term outcomes, e.g., restenosis &
re-intervention, workflow efficiency, and patient safety.
●
Investors & new entrants: With
the strong growth outlook and technology innovation momentum, there are
compelling opportunities for companies offering differentiated DES technologies
or entering underserved markets.
●
Policy-makers & healthcare
payers: Encouraging access to advanced stent technologies, supporting cath-lab
expansion, and ensuring favorable reimbursement will promote wider access and
improved cardiovascular outcomes.
About M2Square Consultancy
We specialize in decoding complexity. From market
forecasting to customer behavior analysis, our services are designed to bridge
the gap between uncertainty and opportunity. Our offerings span the entire
insight lifecycle, including Consulting, Tailored Research, Syndicated Studies,
Trend Tracking, Competitive Intelligence, Pricing and Channel analysis, GTM
Strategy and more. Using a blend of qualitative expertise and data science, we
deliver bespoke solutions that inform bold business moves. Whether you’re
entering a new geography, launching a product, or restructuring a business
model, we help you understand the landscape before you leap. What makes us
different is our obsession with relevance. We don’t deliver static reports; we
craft stories backed by evidence, customized for your strategic needs. Our
advanced data visualization capabilities bring research to life, turning
complexity into clarity. In less than two years, we’ve worked with over 150
organizations across sectors like healthcare, ICT, finance, energy, and
consumer goods, proving our commitment to impact, not just insight. We don’t
just inform; we empower.
Contact:
Website: https://m2squareconsultancy.com/
Email: sales@m2squareconsultancy.com
Phone (IN): +91 80978 74280
Phone (US): +1 929 447 0100
More Trending Reports by M2Square Consultancy
● Erectile Dysfunction Drugs Market Outlook 2033
The erectile dysfunction drug market is
anticipated to grow significantly from 2025 to 2033. By 2025, the market is projected to reach a value of
around USD 4.4 billion. Looking ahead to 2033, it is expected to expand further
to about USD 7.6 billion. This represents an annual growth rate of 7.2% over the
eight years.
● Rare Disease Drugs Market Outlook 2033
The rare disease drugs market growth
is predicted to develop at a compound annual growth rate (CAGR) of 9.6% from
2025 to 2033, when the global rare disease drugs market
forecast revenue is projected to reach USD 364.1 billion in 2033, based on an
average growth pattern.
The global generic drugs market revenue is projected to reach US$746.8 billion by
2033 from US$403.0 billion in 2025. The market is expected to register a CAGR
of 8.2% from 2025 to 2033.
● Antibody Drug Conjugate Market Outlook 2033
The antibody-drug conjugate market is
anticipated to grow significantly from 2025 to 2033. By 2025, the market is
projected to reach a value of around USD 22.1 billion. Looking ahead to 2033,
it is expected to expand further to about USD 12.5 billion. This represents an
annual growth rate of 5.7% over the eight years.
● Oncology Drugs Market Outlook 2033
The oncology drugs market is anticipated to grow
significantly from 2025 to 2033. By 2025, the market is projected to reach a
value of around USD 253.6 billion. Looking ahead to 2033, it is expected to
expand further to about USD 580.2 billion. This represents an annual growth
rate of 11.2% over the eight years.
● Ultomiris Drug Market Outlook 2033
The Ultomiris drug market is anticipated to grow
significantly from 2025 to 2033. By 2025, the market is projected to reach a
value of around USD 14.9 billion. Looking ahead to 2033, it is expected to
expand further to about USD 5.2 billion. This represents an annual growth rate
of 14.4% over the eight years.
● Drug Discovery Outsourcing Market Outlook 2033
The global drug discovery outsourcing market value is projected to reach US$9.7 billion by 2033
from US$4.9 billion in 2025. The market is expected to register a CAGR of 9.1%
during 2025–2033.